Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES-481 for Uncontrolled Glioma-Associated Epilepsy
NCT04737174Phase 2Withdrawn
- Sponsor
- ES Therapeutics LLC
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of es-481 in glioma-associated epilepsy (GRE), glioma, sponsored by ES Therapeutics LLC. Planned start Mar 2021; status: withdrawn.
02
Drugs
es-481
03
Conditions
glioma-associated epilepsy (GRE)glioma
Beyond the preview
Go deeper on NCT04737174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04737174.